Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,957 total articles

Atlantic International Relaunches As Circle8, Reflecting Its Evolution Into A Global Technology and Workforce Solutions Platform

Atlantic International Relaunches As Circle8, Reflecting Its Evolution Into A Global Technology and Workforce Solutions Platform

Atlantic International Corp., trading on Nasdaq under ticker ATLN, announces a corporate name change to Circle8 Group, Inc. with a new ticker symbol CIRC, reflecting its evolution into a global technology and workforce solutions platform with over $1.2 billion annualized revenue. The company appoints Guus Franke as CEO, emphasizing an integrated pl…

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Design Therapeutics has begun dosing patients in its Phase 1 multiple ascending dose clinical trial evaluating DT-818, a GeneTAC® small molecule aimed at selectively reducing transcription of the mutant DMPK allele, addressing the underlying cause of myotonic dystrophy type-1 (DM1). This trial marks a key milestone in developing a potential best-in…

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALX Oncology announced key leadership changes, appointing Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel. Garland succeeds co-founder Corey Goodman, who steps down after over a decade of leadership. These appointments aim to support the company's strategic growth and advancement of its oncology drug pipeline, inclu…

Eos Announces $125 Million Investment for Frontier Power USA, Bringing Expected Frontier Equity Investment up to $375 Million

Eos Announces $125 Million Investment for Frontier Power USA, Bringing Expected Frontier Equity Investment up to $375 Million

Eos Energy Enterprises announced a $75 million equity investment from Hudson Bay Capital Management plus a $50 million direct investment into Frontier Power USA, raising FPUSA's expected equity investment to $375 million. This capital base is projected to support $1.5 billion in project deployment for long-duration zinc-based energy storage solutio…

Eos Energy Announces Updated Terms for Rights Offering

Eos Energy Announces Updated Terms for Rights Offering

Eos Energy Enterprises announced updated terms for a rights offering to its common stock and warrant holders. The offering allows eligible holders to purchase units consisting of common stock and warrants at a 10% discount, to fund the company’s capital contribution to the Frontier Power USA joint venture. The rights offering will be conducted unde…

ZenaTech Reports Annualized Revenue Run Rate of Approximately CAD $33 Million Based on First Quarter 2026 Revenue

ZenaTech Reports Annualized Revenue Run Rate of Approximately CAD $33 Million Based on First Quarter 2026 Revenue

ZenaTech, a Nasdaq-listed technology company specializing in AI-powered drone platforms and Drone as a Service (DaaS), reported an annualized revenue run rate of approximately CAD $33 million based on its Q1 2026 revenue figures. The company attributes growth to its acquisition strategy, integrating under-digitized service businesses and expanding …

Eos Announces Pricing of Registered Direct Offering of Common Stock and Warrants to Fund Investment in Frontier Power USA

Eos Announces Pricing of Registered Direct Offering of Common Stock and Warrants to Fund Investment in Frontier Power USA

Eos Energy Enterprises announced a registered direct offering with Hudson Bay Capital Management raising approximately $75 million through common stock and warrants to fund its contribution to Frontier Power USA Parent, LLC (FPUSA). The financing supports FPUSA’s robust pipeline of 16 GWh long-duration energy storage projects across the U.S., enabl…

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Pyxis Oncology has entered a private placement financing agreement to raise approximately $50 million upfront, with potential additional proceeds of $64 million if warrants are exercised. The funding will extend the company's cash runway into Q2 2027 and support advancement of their lead candidate, MICVO, through key clinical milestones in head and…

Blockfusion and Blue Acquisition Corp. Announce LOIs for Anchor Lease with a Leading AI Customer and $175 Million Convertible Note Financing and Non-Redemption Agreement, and Advancement of Planned Expansion of Niagara Falls Campus

Blockfusion and Blue Acquisition Corp. Announce LOIs for Anchor Lease with a Leading AI Customer and $175 Million Convertible Note Financing and Non-Redemption Agreement, and Advancement of Planned Expansion of Niagara Falls Campus

Blockfusion USA and Blue Acquisition Corp. announced non-binding letters of intent for a 15-year, take-or-pay anchor lease of up to 300 MW with a leading AI customer at Blockfusion's Niagara Falls data center campus, complemented by a $175 million convertible note financing and non-redemption agreement. These moves support capitalizing and expandin…

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors

Palvella Therapeutics, a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies for serious rare skin diseases and vascular malformations, appoints Matt Pauls, an experienced biotech executive and commercial leader, to its Board of Directors. This strategic appointment leverages Pauls' over 25 years of expertise in advancing ra…

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients

FocalTherics announced the launch of the first commercial endometriosis treatment program using its Focal One Robotic HIFU system at Toulouse University Hospital in France. This program marks a significant expansion of the company's minimally invasive therapy aimed at deep infiltrating endometriosis, a condition affecting approximately 38 million w…

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

OptimizeRx Corp. announced the launch of CopayCue™, a next-generation tool integrating real-time prescribing intent data into the electronic prescribing workflow to make brand savings offers more transparent and accessible to healthcare providers and patients. This innovation aims to reduce cost barriers, increase prescription fulfillment rates, an…

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

Following the European Medicines Agency's recommendation to revoke Tavneos' marketing authorization for ANCA-associated vasculitis, InflaRx N.V. is assessing a broadened development strategy in Europe for its anti-C5a antibody vilobelimab and oral C5aR inhibitor izicopan. The company plans to engage with EMA to determine the most efficient path to …

Bilibili Inc. Provides Update on Share Repurchase Program

Bilibili Inc. Provides Update on Share Repurchase Program

Bilibili Inc. has announced an update on its share repurchase program, revealing it has repurchased approximately 1.9 million shares for $31.3 million as of June 30, 2026, and 4.8 million shares totaling $100.1 million over the past six months. This move reflects the company's strategy to enhance shareholder value and confidence in its growth prosp…

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Unicycive Therapeutics announced receipt of a Complete Response Letter from the FDA regarding the resubmitted New Drug Application for oxylanthanum carbonate (OLC), an investigational phosphate binder for hyperphosphatemia in dialysis patients. The FDA did not express concerns about clinical data, but the CRL stems from unresolved third-party manuf…

Aurora Mobile’s JPush Partners with CICC Wealth Management to Enhance the Digital Wealth Management Experience

Aurora Mobile’s JPush Partners with CICC Wealth Management to Enhance the Digital Wealth Management Experience

Aurora Mobile Limited (NASDAQ: JG) has partnered with China CICC Wealth Management to integrate its JPush intelligent push notification solution into the CICC Wealth Management App. This integration aims to improve the app's communication infrastructure, enhancing reliability, compliance, and personalization in delivering transaction alerts and adv…

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

AC Immune reported interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24, an anti-Abeta active immunotherapy for prodromal Alzheimer's disease. The treatment was generally safe and well tolerated across three patient cohorts, showing a clear dose-response in anti-Abeta antibody production. The ongoing fourth cohort is testing an enhanced …

Tilray Beer Brands SweetWater, 10 Barrel, Breckenridge, BrewDog, Montauk, Blue Point, Hop Valley and Terrapin Tap into America’s 250th with Fourth of July Celebrations Nationwide

Tilray Beer Brands SweetWater, 10 Barrel, Breckenridge, BrewDog, Montauk, Blue Point, Hop Valley and Terrapin Tap into America’s 250th with Fourth of July Celebrations Nationwide

Tilray Brands, Inc., through its U.S. beer division Tilray Beer, is hosting a nationwide series of Fourth of July events featuring its craft beer brands such as SweetWater, 10 Barrel, Breckenridge, BrewDog, Montauk, Blue Point, Hop Valley, and Terrapin. The celebrations will include live music, exclusive merchandise, special beer deals, and local e…

RUM Group Inc. Announces the Filing of Updated Investor Materials

RUM Group Inc. Announces the Filing of Updated Investor Materials

RUM Group Inc., a NASDAQ-listed company integrating video platform Rumble and AI infrastructure firm Quake AI, announced updated investor materials emphasizing significant GPU utilization increases, secured multi-year contracts worth $270 million for advanced NVIDIA GPU deployments at its Amsterdam data center, and a 50% reduction in debt facilitie…